AbbVie Inc. (ABBV)
AbbVie Statistics
Share Statistics
AbbVie has 1.77B shares outstanding. The number of shares has increased by 0.18% in one year.
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | 0.18% |
| Shares Change (QoQ) | 0.1% |
| Owned by Institutions (%) | 71.96% |
| Shares Floating | 1.77B |
| Failed to Deliver (FTD) Shares | 20 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 17.14M, so 0.97% of the outstanding shares have been sold short.
| Short Interest | 17.14M |
| Short % of Shares Out | 0.97% |
| Short % of Float | 0.97% |
| Short Ratio (days to cover) | 2.22 |
Valuation Ratios
The PE ratio is 73.33 and the forward PE ratio is 12.33. AbbVie's PEG ratio is -6.46.
| PE Ratio | 73.33 |
| Forward PE | 12.33 |
| PS Ratio | 5.57 |
| Forward PS | 4 |
| PB Ratio | 94.34 |
| P/FCF Ratio | 16.68 |
| PEG Ratio | -6.46 |
Enterprise Valuation
AbbVie has an Enterprise Value (EV) of 375.31B.
| EV / Sales | 6.66 |
| EV / EBITDA | 25.17 |
| EV / EBIT | 19.96 |
| EV / FCF | 19.96 |
Financial Position
The company has a current ratio of 0.66, with a Debt / Equity ratio of 20.19.
| Current Ratio | 0.66 |
| Quick Ratio | 0.55 |
| Debt / Equity | 20.19 |
| Debt / EBITDA | 4.5 |
| Debt / FCF | 3.57 |
| Interest Coverage | 3.25 |
Financial Efficiency
Return on Equity is 128.66% and Return on Invested Capital is 10.21%.
| Return on Equity | 128.66% |
| Return on Assets | 3.17% |
| Return on Invested Capital | 10.21% |
| Revenue Per Employee | $1.02M |
| Profits Per Employee | $77.78K |
| Employee Count | 55,000 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 4.04 |
Taxes
| Income Tax | -570M |
| Effective Tax Rate | -15.34% |
Stock Price Statistics
The stock price has increased by 4.91% in the last 52 weeks. The beta is 0.54, so AbbVie's price volatility has been higher than the market average.
| Beta | 0.54 |
| 52-Week Price Change | 4.91% |
| 50-Day Moving Average | 199.44 |
| 200-Day Moving Average | 187.99 |
| Relative Strength Index (RSI) | 30.22 |
| Average Volume (20 Days) | 7.43M |
Income Statement
In the last 12 months, AbbVie had revenue of 56.33B and earned 4.28B in profits. Earnings per share was 2.42.
| Revenue | 56.33B |
| Gross Profit | 39.43B |
| Operating Income | 9.14B |
| Net Income | 4.28B |
| EBITDA | 14.91B |
| EBIT | 6.52B |
| Earnings Per Share (EPS) | 2.42 |
Balance Sheet
The company has 5.52B in cash and 67.14B in debt, giving a net cash position of -61.62B.
| Cash & Cash Equivalents | 5.52B |
| Total Debt | 67.14B |
| Net Cash | -61.62B |
| Retained Earnings | -7.9B |
| Total Assets | 135.16B |
| Working Capital | -13.17B |
Cash Flow
In the last 12 months, operating cash flow was 18.81B and capital expenditures 0, giving a free cash flow of 18.81B.
| Operating Cash Flow | 18.81B |
| Capital Expenditures | 0 |
| Free Cash Flow | 18.81B |
| FCF Per Share | 10.65 |
Margins
Gross margin is 69.99%, with operating and profit margins of 16.22% and 7.59%.
| Gross Margin | 69.99% |
| Operating Margin | 16.22% |
| Pretax Margin | 6.6% |
| Profit Margin | 7.59% |
| EBITDA Margin | 26.47% |
| EBIT Margin | 16.22% |
| FCF Margin | 33.38% |
Dividends & Yields
ABBV pays an annual dividend of $7.93, which amounts to a dividend yield of 3.61%.
| Dividend Per Share | $7.93 |
| Dividend Yield | 3.61% |
| Dividend Growth (YoY) | 5.81% |
| Payout Ratio | 333.19% |
| Earnings Yield | 1.36% |
| FCF Yield | 6% |
Analyst Forecast
The average price target for ABBV is $214, which is 23.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $214 |
| Price Target Difference | 23.9% |
| Analyst Consensus | Buy |
| Analyst Count | 20 |
Scores
| Altman Z-Score | 1.9 |
| Piotroski F-Score | 5 |